Palivizumab

Type: Product
Name: Palivizumab
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

Stock Update (NYSE:ABBV): AbbVie Cystic Fibrosis Scholarship Program Awards 40 Student Scholars With Annual Academic Awards

[PR Newswire] – NORTH CHICAGO, Ill., Aug. 18, 2014 /PRNewswire/ — AbbVie today announced the 40 outstanding students with cystic fibrosis (CF) who will each receive $2,500 to pursue their undergraduate or graduate school education during the 2014-2015 ... [Published Jutia Group - Aug 18 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

Novavax Reports Second-Quarter 2014 Financial Results

GAITHERSBURG, Md., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today reported ... [Published Virtual Strategy Magazine - Aug 06 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

New AAP guidance for RSV drug spurs manufacturer reaction

The American Academy of Pediatrics (AAP) revision of its recommendations for use of palivizumab (Synagis, MedImmune Specialty Care Division of AstraZeneca ) for respiratory syncytial virus (RSV) in infants has fueled a reaction from the drug’s manufa ... [Published Formulary Journal - Aug 05 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

In Brief: Erie physician named second VP of Osteopathic Association

Frank M. Tursi, D.O., was recently elected second vice president of the American Osteopathic Association during the AOA's annual house of delegates meeting July 18-20 in Chicago.Tursi is a family physician with Medical Associates of Erie. He is also a ... [Published Erie Times-News - Aug 04 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

AZ upgrades its forecast for 2014

AstraZeneca Plc has upgraded its financial guidance for 2014 following an increase in revenue in the second quarter and the successful launch of a new medicine for Type 2 diabetes in the US. Sales in China also rose by 23% on a constant currency basi ... [Published MedNous - Jul 31 2014]
First reported Jul 29 2014 - Updated Jul 30 2014 - 2 reports

New AAP Guidelines for Treating RSV

New AAP Guidelines for Treating RSVFor the second time in two years, the American Academy of Pediatrics is calling for doctors to scale back the use of  palivizumab prophylaxis when it comes to treating RSV in infants.Respiratory syncytial virus , or ... [Published The Bump - Jul 30 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

AstraZeneca rolls out preemie newspaper ads to fight Synagis limits

Drugmakers cheer when influential doctors' groups revise treatment guidelines to include new drugs. But as AstraZeneca's ( $AZN ) MedImmune unit knows, those groups can backpedal. With the American Academy of Pediatrics backing new limits on its antiviral ... [Published FiercePharma - Jul 29 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

AstraZeneca PLC Fights With Pediatrician Group Over Preemie Drug Guidelines

Once again, there is controversy over an expensive drug for premature babies.At issue are new American Academy of Pediatrics guidelines that recommend scaling back usage of a drug called Synagis, which costs several thousand dollars and is sold by AstraZeneca ... [Published BioSpace - Jul 29 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 2 reports

AAP updates guidance on palivizumab prophylaxis for RSV

The AAP’s Red Book Committee updated guidance for use of palivizumab prophylaxis among infants and young children with increased risk for hospitalization for respiratory syncytial virus infection.The updated recommendations reflect new information regarding ... [Published Orthopedics Today - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Premature Babies Drug in Middle of Clash Between Creator and Pediatrican Group

An expensive drug that is given mainly to premature babies is at the middle of a clash between the creator and the nation’s top pediatrician group, which has recommended cutting back on use of the medication. The clash involves new procedures that have ... [Published The Guardian Express - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 4 reports

Pediatricians clash with maker of drug for babies

Leading pediatrician's group says prescription Synagis should not be given to so many kids; drugmaker fires back ... [Published Latest Econwatch Headlines - CBS News - Jul 28 2014]
Entities: Drugs, Palivizumab
First reported Jul 25 2014 - Updated Jul 26 2014 - 1 reports

AbbVie's (ABBV) CEO Richard Gonzalez on Q2 2014 Results - Earnings Call Transcript

OperatorGood morning and thank you for standing by. Welcome to the AbbVie Second 2014 Earnings Conference Call. All participants will be able to listen-only. This conference is being recorded by AbbVie.I would now like to introduce Mr. Larry Peepo, Vice ... [Published Seeking Alpha - Jul 25 2014]

Quotes

...We continue to make progress in our RSV and influenza vaccine development programs," said Stanley C Erck, President and CEO of Novavax. "The second half of 2014 will be the most productive period in the company's history. We plan to initiate 4 clinical studies before the end of 2014; RSV maternal immunization, pediatric and elderly, as well as a seasonal influenza clinical trial. We also plan to initiate a combination RSV/seasonal influenza clinical trial in early 2015. In addition, we plan to present pre-clinical and clinical data at several important medical meetings later this year."
"And there are alternatives to handshakes. You see them on telly all the time" Whitworth said
...measures and a reconciliation of Core to Reported financial measures Pascal Soriot, Chief Executive Officer, commenting on the results, said "We have made significant progress in the first half of the year, with visible momentum across our cardiovascular, diabetes and respiratory franchises as well as strong growth in the emerging markets. This has driven revenue growth for the second consecutive quarter and achieved a 13% increase in Core EPS in the quarter. The pace of execution of our strategy and the underlying performance of our teams give us confidence to raise 2014"

More Content

All (23) | News (21) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Stock Update (NYSE:ABBV): AbbVie Cystic Fibrosi... [Published Jutia Group - Aug 18 2014]
Novavax Reports Second-Quarter 2014 Financial R... [Published Virtual Strategy Magazine - Aug 06 2014]
New AAP guidance for RSV drug spurs manufacture... [Published Formulary Journal - Aug 05 2014]
In Brief: Erie physician named second VP of Ost... [Published Erie Times-News - Aug 04 2014]
AZ upgrades its forecast for 2014 [Published MedNous - Jul 31 2014]
Motavizumab Treatment of Infants Hospitalized W... [Published General Medicine eJournal - Jul 31 2014]
AstraZeneca PLC : Second Quarter & Half Year Re... [Published Investegate - Jul 31 2014]
New AAP Guidelines for Treating RSV [Published The Bump - Jul 30 2014]
New RSV Policy [Published ConchoValleyHomepage.com - Jul 29 2014]
AstraZeneca rolls out preemie newspaper ads to ... [Published FiercePharma - Jul 29 2014]
AstraZeneca PLC Fights With Pediatrician Group ... [Published BioSpace - Jul 29 2014]
AAP updates guidance on palivizumab prophylaxis... [Published Orthopedics Today - Jul 28 2014]
Premature Babies Drug in Middle of Clash Betwee... [Published The Guardian Express - Jul 28 2014]
Pediatricians clash with maker of drug for babies [Published Latest Econwatch Headlines - CBS News - Jul 28 2014]
Virus drugmaker fights pediatricians' new advice [Published Central Utah Daily Herald - Jul 28 2014]
RSV Recommendations [Published American Academy of Pediatrics - Jul 28 2014]
Virus drugmaker fights pediatricians [Published News-Journal - Jul 28 2014]
In Brief: Virus drugmaker fights pediatricians'... [Published Erie Times-News - Jul 28 2014]
AbbVie's (ABBV) CEO Richard Gonzalez on Q2 2014... [Published Seeking Alpha - Jul 25 2014]
AbbVie Q2 Profit Rises, Results Beat View; Affi... [Published RTTNews.com - Jul 25 2014]
Market Update (NYSE:ABBV): AbbVie to Host Secon... [Published Jutia Group - Jul 23 2014]
Annual Financial Report [Published TrustNet - Mar 20 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 06 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Pediatricians clash with maker of drug for babies [Published Latest Econwatch Headlines - CBS News - Jul 28 2014]
Leading pediatrician's group says prescription Synagis should not be given to so many kids; drugmaker fires back ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 06 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.